Start-Ups Spun out of SPARK
SPARK has instigated the formation of numerous start-ups working to bring research from bench to bedside
SPARKing Industry in Start-Ups
Alexo is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Auration Biotech Inc.
Creates products that restore or maintain hearing.
ab initio biotherapeutics
Using a proprietary directed evolution discovery platform to create the next generation of protein therapeutics.
Allertope's rapidly-dissolving microneedles form the basis of a new skin test to determine the severity of a person’s food allergies.
- Researches Hep C/D
- Company raised over $3.4M from STTR and QTDP grants and $7.1M series A from VCs
- Tumor imaging
- $400K in SBIR
Organ-I developed Dx for early kidney rejection; acquired by Immucor. Their product, k-SORT test, is commercially available.
ALDEA Pharmaceuticals (now Aviv Therapeutics)
ALDEA works to combat oxidative stress diseases; a $36M Series A+B. Completing phase 2B trial in Australia.
Balance researchers Down’s Syndrome; they received $2.2M in SBIR funding, and $21M in series A and B. They are completing a phase 2 clinical trial in Australia.
Altitude is developing a small molecule activator of novel target that both increases insulin sensitivity and endothelial function.
- Basal cell carcinoma
- 2014 Harrington Scholar
- Company raised $8M
- Automated DNA/RNA extraction, quantitation, and enrichment platform
- Named BayBio FAST Company
- $150K SBIR
Developed diagnostic for cardiac transplant rejections; acquired by CareDx.
IGIStat developed a diagnostic that can rapidly distinguish between Type 1 (T1D) and Type 2 diabetes (T2D); named BayBio FAST company.
- Pulmonary arterial hypertension
- Granted Orphan Drug Status 3/15.
- Celiac disease
- $10M series A
- BriDG collaboration with NCATS to fund IND-enabling studies
- Preeclampsia technology
- In StartX incubator
- $80K from March of Dimes
- Acquired by Progenity
Eiccose raised funding for Phase 2 clinical trial of pulmonary arterial hypertension.
- Anti-viral for Ebola, Dengue and other viruses
- In StartX incubator
- Raised Series A & B funding.
Eidos developed a novel small molecule to treat transthyretin- based amyloidosis.
SPARK IP licensed or optioned to established companies:
Thiolex Pharma: Cystic fibrosis; commercially available through Bioadvantex Pharma
Jordan River Pharmaceuticals: Brain cancer
La Jolla Pharmaceutical: Neonatal jaundice
InSilixa: Bacterial Diagnostics (*no IP, but co-developing)
Cortice Biosciences: Alzheimer’s disease